Welcome to our dedicated page for CACTUS ACQUISITION 1 news (Ticker: CCTS), a resource for investors and traders seeking the latest updates and insights on CACTUS ACQUISITION 1 stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CACTUS ACQUISITION 1's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CACTUS ACQUISITION 1's position in the market.
Summary not available.
Cactus Acquisition Corp. 1 Ltd. (Nasdaq: CCTS) has announced plans for an extraordinary meeting on April 20, 2023, to vote on extending the deadline for its initial business combination from May 2, 2023, to November 2, 2023. This extension requires approval from shareholders and aims to enable further strategic opportunities. The Company’s sponsor, Cactus Healthcare Management, will contribute funds to the trust account, potentially amounting to $40,000 or $0.02 per public share. Additionally, any funds will remain untouched for excise tax payments under the Inflation Reduction Act of 2022. If approved, the Sponsor will also convert its Class B shares into Class A shares, increasing the number of outstanding Class A shares. The trust account will yield interest at approximately 4.5% per annum, although this rate may vary.
Cactus Acquisition Corp. 1 Limited (NasdaqGM: CCTS, CCTSU and CCTSW) filed its annual report on Form 10-K for the year ending December 31, 2021, with the SEC on March 31, 2022. The company is focused on mergers and acquisitions in technology-based healthcare sectors, particularly those related to Israel. Led by CEO Ofer Gonen, the firm aims to combine with innovative businesses in this space. The report and other filings can be accessed on the company website or the SEC's site.